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Abstract

SILDENAFIL ATTENUATES ETHANOL-INDUCED CARDIOMYOCYTE INJURY
AND PRESERVES CARDIAC FUNCTION THROUGH PROTEIN KINASE GDEPENDENT SIGNALING
By Gregory R. Sturz, PhD
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013
Major Director: Rakesh Kukreja, PhD
Lipman Professor of Cardiology, Dept. of Internal Medicine, Division of Cardiology

Background: Ethanol is a cardiotoxic substance that damages the heart by increasing
apoptosis, free radical formation and calcium overloading. Consequently, there is an
increase in cell death leaving fewer functioning myocytes leading to heart failure.
Sildenafil is a phosphodiesterase type-5 (PDE-5) inhibitor approved for treatment of
erectile dysfunction. Studies from our lab have demonstrated that PDE-5 inhibition reduces
myocardial infarct size and attenuates post-ischemic cardiac dysfunction in both ischemia-
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reperfusion and permanent coronary artery ligation models. Therefore, in the present study,
we hypothesized that treatment with sildenafil will prevent cardiotoxicity associated with
acute alcohol exposure by reducing myocyte apoptosis and preserving cardiac function
through PKG signaling.
Methods and Results: Adult cardiomyocytes were isolated and treated with 100 mM of
100% ethanol ± 10 µM sildenafil. At 24 hours necrosis was assessed via trypan blue
exclusion assay, JC-1 staining assessed mitochondrial membrane potential and ROS
production was measured by DCF fluorescence. At 48 hours apoptosis was assessed by
TUNEL assay. Ethanol increased the rate of necrotic and apoptotic cell death. This was
attenuated by co-treatment with sildenafil. Ethanol disrupted the mitochondrial membrane
potential and increased ROS production. Sildenafil preserved mitochondrial membrane
potential and attenuated ROS production. Treatment of myocytes with 5-HD, a
mitochondrial K+atp channel antagonist, blocked the protective effect of sildenafil.
Knockdown of PKG using adenoviral siRNA blocked the protective effect of sildenafil,
while overexpression of PKG1α conferred protection against ethanol cytotoxicity. To
further demonstrate the effect of sildenafil ethanol-cardiotoxicity in vivo, mice were treated
with ethanol (3 g/kg/day) with or without sildenafil (0.7 mg/kg) by i.p. injection for three
consecutive days. After treatment, the animals were sacrificed and the hearts removed and
perfused on a Langendorff system to measure function. After functional analysis, apoptosis
and PKG activity was measured in the heart samples. Ethanol decreased the rate-force
product and increased myocardial apoptosis. Sildenafil preserved cardiac function and
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significantly reduced apoptosis. Sildenafil treated myocardium also showed an increase in
PKG activity.
Conclusion: Sildenafil attenuates the toxic effect of ethanol by reducing apoptosis and
maintaining the mitochondrial integrity in cardiomyocytes. Sildenafil also preserved
cardiac function in ethanol-treated mice. Protein kinase G-dependent signaling plays a
critical role in attenuating cardiotoxic effect of ethanol.

Introduction
The intoxicating effects of alcohol have been known by humanity since ancient
times. In fact, the fermentation of sugar into ethanol and the distillation of spirits is one of
the earliest examples of biotechnology in human history. In stark contrast to its positive
hedonic effects, ethanol (CH3-CH2-OH) is a toxic substance. Its chemical structure and
small size enable it to distribute to every cell of the body. As a result, alcohol abuse has
been related to over sixty different disorders and chronic health conditions1. Alcohol
abuse is the third leading cause of preventable death. In the United States, alcohol is
implicated in the death of more than 100,000 people annually2. Globally, harmful alcohol
use is responsible for 2.5 million deaths annually1.

Effect of Alcohol on the Heart
The effect of alcoholic beverages on the heart and vascular system is complex. The
amount consumed, drinking pattern and genetics all influence the health consequences of
imbibing alcohol-containing beverages. Despite this complexity, the effect of alcohol on
cardiovascular risk is consistently depicted as a J-shaped curve. The consumption of
alcohol in moderation confers a decreased cardiovascular risk as compared to abstainers.
Subsequently, people who consume larger amounts of alcohol have increasing
cardiovascular risk3. The mechanism by which alcohol-containing beverages lower
1
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cardiovascular risk is poorly understood. This effect is further complicated by the fact that
the choice of alcoholic beverage also influences cardiovascular risk. For example, wine is
more “heart healthy” than distilled spirits or beer. This is due to the presence of
cardioprotective compounds found in wine (i.e. resveratrol) 4. Regardless of form, large
doses of ethanol are toxic to the heart. They are especially toxic when consumed
chronically.
This chronic consumption leads to cardiac damage and cardiac muscle disease,
called alcoholic cardiomyopathy (ACM). ACM is a specific form of non-ischemic dilated
cardiomyopathy5-7. Unlike viral or autoimmune cardiomyopathies, there is no specific test
or immunohistochemical marker for ACM and the gross/histological findings are
indistinguishable from idiopathic dilated cardiomyopathy8. The diagnosis of ACM is a
presumptive one and should be considered in a patient with cardiac damage, whose history
is significant for alcohol abuse. It should be noted that the diagnosis of ACM might be
considered only after other forms of dilated cardiomyopathy have been ruled out.
The progression of ACM is initiated by alcohol abuse. Alcohol abuse damages the
heart and its ability to pump blood efficiently. Concurrent to the functional impairment,
several morphological changes are evident in the damaged heart such as cardiomegaly,
dilated left ventricle (LV), a normal to reduced cardiac wall thickness, and an increased LV
mass8. Under histological analysis, myocardium will display disruptions of myofibrillary
architecture 9. These morphologic and functional changes mark the asymptomatic phase of
ACM. Continued abuse of alcohol leads a progressive and inevitable decline into
symptomatic cardiomyopathy and heart failure.
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Ethanol, Acetaldehyde and Cytotoxicity
A singular pathologic mechanism for the generation of ACM has yet to be clearly
elucidated. The task of deciphering such a mechanism is complicated by the fact that
ethanol and its major metabolite, acetaldehyde, are both cardiotoxic compounds. When
ethanol is imbibed, it is passed to the stomach and small intestine where it is rapidly
absorbed by gastric and intestinal mucosa. The portal circulation transports ethanol to the
liver, where it is subjected to first pass metabolism. The liver is the major site for alcohol
metabolism, although other organs, including the heart may participate. Ethanol is
oxidized by the cytosolic enzyme alcohol dehydrogenase (ADH) to produce acetaldehyde.
Acetaldehyde is subsequently oxidized by the mitochondrial matrix protein aldehyde
dehydrogenase to form acetate. Acetate is then removed from the circulation and excreted
from the body. Cardiotoxicity, whether it is directly from ethanol or indirectly by
acetaldehyde, appears to be mediated by several mechanisms, including apoptosis,
oxidative stress, contractile protein dysfunction, organelle dysfunction, and neurohormonal
activation.

Cardiomyocyte Loss
Cardiomyocyte loss appears to be central to the development of ACM 10.
Cardiomyocytes may die either by necrosis or apoptosis. Necrosis is commonly seen
during myocardial infarction and ischemic cardiomyopathy, but is rarely observed in nonischemic dilated cardiomyopathy. The myocardium of patients with ACM had disrupted
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striations and pynknotic nuclei, an observation consistent with apoptosis 11. More recently,
hearts from patients with a history of alcoholism displayed a higher apoptotic index, as
assessed by TUNEL assay. Also, they displayed altered BAX/BCL-2 ratios, indicating a
pro-apoptotic state 12. These studies demonstrated the relationship between long-term
ethanol consumption and apoptosis in human samples.
Murine myocardium also displayed an increase in apoptosis and pro-apoptotic
signaling following ethanol challenge (3g/kg/day i.p. for three consecutive days) 13. In the
same study, Ren’s group utilized a novel cardiac-specific over-expression of ADH and
showed an increase in the rate of apoptosis compared to ethanol alone by “overloading” the
myocardium with acetaldehyde. These studies demonstrate that ethanol and acetaldehyde
damage the myocardium via apoptotic cell death.

Oxidative Stress
Oxidative stress plays a role in the development of cardiotoxicity leading to ACM.
The oxidation of ethanol and acetaldehyde leads to free radical production14,15. The same
is true for the microsomal ethanol oxidation system (MEOS) as well as the catalase
pathway for the degradation of ethanol 9. Glutathione (GSH) is the major, although not the
only, antioxidant system employed by the cardiomyocyte9,16. GSH exists in the
cardiomyocyte in either reduced or oxidized state. In the reduced state, it is able to donate
a reducing equivalent to reactive molecules such as free radicals. In doing so, GSH itself
becomes reactive, only then to interact with another glutathione to form glutathione
disulfide. Mice acutely fed ethanol by gavage (5g/kg) demonstrated a decreased cardiac
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mitochondrial GSH as well as a reduced cytosolic GSH. This was interpreted to be an
indicator of acute oxidative stress17. The role of oxidant stress in cardiovascular
cytotoxicity has been further supported through the use of transgenic mice. Catalase is a
peroxisomal enzyme that participates in the oxidation of ethanol. Catalase couples the
conversion of H2O2 to H2O, to the oxidation of ethanol. In light of the role of catalase in
metabolizing ethanol as well as detoxifying H2O2, it was proposed that by elevating the
cardiac expression of catalase could shift the cardiomyocyte’s redox state to a more proantioxidant state and prevent oxidative cell damage 18. Accordingly, it was demonstrated
that the over-expression of catalase maintained the mechanical function of cardiomyocyte
in the presence of ethanol through preserved Ca2+ handling and anti-apoptotic cell
signaling 15,18.
The accumulation of reactive oxygen species (ROS) generated by the metabolism
of ethanol and acetaldehyde, coupled with the depletion of oxidant defenses, creates an
environment capable of producing cellular damage. ROS cause damage to cellular
components such as carbohydrates, proteins, lipids and nucleic acids.

Contractile Protein Dysfunction
Exposing cardiomyocytes to ethanol in vitro produces a negative inotropic effect.
This dose-dependent response was subsequently found to be non-linear, suggesting that
ethanol effects cardiomyocyte contraction in several ways 19. One possible explanation for
this observation is that ethanol negatively affects cardiac contractile proteins. It was
demonstrated that chronic alcohol consumption resulted in a decreased association between
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actin and myosin in vitro 20. These results suggested that ethanol-induced changes in
protein function or synthesis might lead to the development of ACM. Chronic ethanol
administration reduced the synthesis of myofibrillar and sarcoplasmic proteins 21. A more
comprehensive examination of cardiac muscle protein expression revealed myofibrillar,
sarcoplasmic, membrane-associated as well as mitochondrial proteins were all reduced,
although the majority of cardiac proteins were not affected by ethanol administration19
These data support the hypothesis that alcohol may exert its deleterious effect by
chronically changing the expression patterns of cardiac protein expression, leading to
contractile defects and eventually overt cardiomyopathy.

Organelle Dysfunction
Electron microscopy has revealed damage to the intracellular organelles of the
myocardium of chronically alcohol-dependent patients 22. In addition to damage and
disarray of the contractile elements, alcohol caused damage to the mitochondria and the
sarcoplasmic reticulum. The mitochondria were increased in number, enlarged, and the
structure of the mitochondrial cristae also appeared abnormal. The sarcoplasmic reticulum
was distended, cystic in appearance and contained increased fatty deposits.
An alternate, non-oxidative pathway for the metabolism of ethanol may explain the
organelle damage observed in the alcoholic heart. Ethanol can be converted to fatty acid
ethyl esters (FAEEs). This reaction is catalyzed by FAEE synthase, which has been
reported to be present in the heart, brain and pancreas23. When excessive alcohol is
consumed, FAEEs accumulate in the mitochondria of the heart. This accumulation results
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in the in the inhibition of both mitochondrial respiration and enzymes of the tricarboxylic
acid cycle8. Cardiomyocytes rely heavily on mitochondrial respiration for ATP production
and damage to these processes result in cardiomyocyte death.
Concomitant to the respiratory defect, there is a disruption in the mitochondria’s
ability to sequester calcium. FAEEs will also disrupt the function of the sarcoplasmic
reticulum. As FAEEs accumulate, there is a dose-dependent depletion of sarcoplasmic
reticulum calcium8. Although direct effects of ethanol on myocardial voltage-gated
calcium channels cannot be ruled out, the combined defects in mitochondrial and
sarcoplasmic reticulum calcium handling may underlie the contractile defects seen in
ACM.

Neurohormonal Activation
Ethanol and acetaldehyde have negative effects on the cardiovascular system via
neurohormonal activation. While ethanol itself is a cardiac depressant, circulating
acetaldehyde produces vasoconstriction, positive inotropy and positive chronotropy at
concentrations < 3 mM9. This effect is mediated through the release of norepinephrine via
intramural sympathetic nerve fibers innervating the heart8. Increased levels of circulating
catecholamines have a well-established role in the progression of heart failure and are
associated with hypertrophy, apoptosis and LV remodeling8. This point is clearly
illustrated, as β-antagonist therapy has become a mainstay in the management of heart
failure.
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The ingestion of ethanol activates the renin-angiotensin system (RAS) and is
associated with the development and potentiation of heart failure. Cheng et al investigated
the role of RAS activation in the development of ACM, by blocking the angiotensin II type
I receptor with irbsartan24.

These investigators demonstrated that chronic alcohol

administration to dogs resulted in sustained activation of RAS followed by LV dilation and
dysfunction as well as cardiomyocyte contractile dysfunction. The co-administration of
irbsartan blunted RAS activation, prevented pathologic changes to the LV and prevented
the contractile defect of cardiomyocytes. These data support the hypothesis that hormonal
activation of RAS contributes to the development of ACM. The weakness of this study is
that it fails to establish the causal relationship between RAS activation and LV
dysfunction. It is possible that RAS activation is an unfortunate downstream sequelae of
ethanol ingestion that promotes the progression of asymptomatic ACM to ventricular
dilation and then failure.

Treatment for Alcoholic Cardiomyopathy
The foundation for treating ACM has relied on the patient abstaining from alcohol.
While effective in preventing the progression of ACM, this strategy has proven to be
difficult. Clinically, it is difficult, and even dangerous, to convince alcohol-dependent
subjects to stop drinking as alcoholics exhibit high levels of both physical and
psychological addiction to ethanol. Furthermore, alcoholics display a high rate of
recidivism, which leads to progression of disease. Without complete abstinence from
alcohol, the 4-year mortality rate after developing ACM approaches 50%8. These factors
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limit the effectiveness of abstinence as a treatment strategy for ACM. Pharmacologic
treatment for ACM is also lacking. Recommendations for treating ACM rely on the
general guidelines for treating heart failure, and include diuretics, ACE-inhibitors/ARBs,
β-antagonists, and cardiac glycosides. Currently, there is no treatment that specifically
addresses the pathologic mechanisms that underlie ACM, which is cell loss.

In summary, the mechanism by which ethanol exerts its toxic effect on
myocardium is poorly understood and complicated by multiple substrates producing
multiple toxic effects. The degree to which, apoptosis, oxidative stress, contractile protein
dysfunction, organelle dysfunction and neurohormonal activation each contribute to the
development of ACM is not known (Figure 1). Consequently, the treatment for ACM is
non-specific and relies on the general guidelines for treating heart failure. This highlights
the need for studies that address both the specific pathologic mechanisms that underlie
cellular toxicity associated with consuming ethanol and disease directed treatments.

Nitric Oxide-Mediated Cell Signaling
Drugs like nitroglycerine and amyl nitrite have long been known for their powerful
vasodilatory effect. Yet, the mechanism by which they worked was not well understood
until the 1980s when it was discovered that vascular endothelial cells release nitric oxide
(NO) and it is this gaseous transmitter that functions as a vasodilator. At that time, the idea
that a gas, produced by one cell could travel to, cross the cell membrane and influence the
function of another cell was an entirely novel concept. In 1998, three scientists won the
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Nobel Prize for this discovery. Since that time nitric oxide has been found to participate in
a number of cellular processes, such as the homeostatic maintenance of blood pressure, the
penile erection, phagocyte respiratory burst, and neuronal signaling.
The cellular signaling involved in the penile erection serves as a prototype for NOmediated cell signaling. NO is produced in neurons and vascular endothelial cells by nitric
oxide synthase (NOS) from the precursor, L-arginine. Cavernosal smooth muscle cells are
normally kept contracted under the influence of α-adrenergic stimulation. In response to
erotic stimuli cavernosal parasympathetic nerves release acetylcholine. Subsequently, nonadrenergic, non-cholinergic nerves and vascular endothelial cells release nitric oxide (NO).
NO rapidly diffuses into smooth muscle cells and activates guanylyl cyclase, converting
GTP into cGMP. cGMP accumulation leads to activation of the cGMP-dependent protein
kinase (PKG). PKG, a serine/threonine kinase, initiates a signaling cascade that ultimately
leads to dephosphorylation of the Ca2+/calmodulin-dependent myosin light chain kinase.
The result is smooth muscle relaxation and vasodilation of the arteries that bring blood to
the penis. Compression of the corpus spongiosum restricts the flow of blood out of the
penis creating a discrepancy between penile inflow and outflow. Intracavernosal pressure
rises and results in the penile erection.

NO-mediated Cell Signaling and Neural Protection against Alcohol Toxicity
Maternal alcohol abuse causes fetal neuron death. This loss of neurons leads to
microencephaly and contributes the fetal alcohol syndrome phenotype. NO is present in
neurons and is produced by neuronal NOS (nNOS). The absence of nNOS left mice more

11
susceptible to the damaging effects of alcohol in the developing brain25, conversely the
overexpression of nNOS conferred a neuroprotective phenotype by reducing neuronal
losses26. Further investigation revealed that it was the NO-mediated signaling pathway
that was responsible for protecting neurons against ethanol toxicity25. In this model, it was
proposed that the NO-cGMP-PKG signaling pathway conferred neuroprotection against
ethanol through NF-κB25. NF-κB is a transcription factor that is normally located in the
cytosol and is complexed with its inhibitory factor IkappaB. PKG was demonstrated to
specifically phosphorylate IkappaB, releasing NF-κB to translocate to the nucleus and
influence gene transcription27. The mechanism by which NF-κB confers its protective
influence is not currently clear, however, it is believed that it alters the regulatory genes of
the apoptosis pathway.

Phosphodiesterases
Phosphodiesterases (PDEs) are a class of enzymes that catalyze the hydrolysis of
one of the ester bonds of cyclic nucleotides. Thus far, eleven isoforms have been found in
mammalian tissue28. Each varies in its tissue distribution as well as its specificity for
cyclic nucleotide (e.g. cAMP or cGMP). PDE type 5 is cGMP specific and is highly
expressed in the corpus cavernosum. It catalyzes the breakdown of cGMP into 5’ GMP,
depleting the intracellular pool of cGMP and inhibiting NO-mediated cell signaling.
Sildenafil is a specific PDE5 antagonist. It is structurally similar to cGMP and
competes for binding at the catalytic site of PDE5. The inhibition of PDE5 prevents the
breakdown of cGMP and allows it to more readily accumulate. The net result is the
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potentiation of NO-mediated cell signaling and enhanced penile tumescence. Initial
studies with sildenafil focused on using it as a treatment for hypertension and angina
pectoris. The theory being that PDE5 inhibition would lead to systemic and coronary
artery dilation. Unfortunately, this theory did not turn out to be valid. However, many of
the study volunteers reported fortuitous side effect; improved quality of their erections. In
1998, the Pfizer Company released sildenafil under the trade name Viagra™. At that time,
sildenafil was the first pharmacologic treatment for erectile dysfunction. Two additional
agents in this class (tadalafil [CialisTM], vardenafil [LevitraTM]) have also been developed
and approved by the FDA for treatment of erectile dysfunction. More recently, avanafil
(Stendra™) has been approved for the same purpose. Both sildenafil and tadalafil have
also been approved for treatment of pulmonary hypertension. In recent years, there has
been tremendous interest in identifying new clinical uses of PDE-5 inhibitors in
cardiovascular protection29-31.

Sildenafil and Cardioprotection
Kukreja and colleagues published the first study demonstrating the cardioprotective
effect of sildenafil in 200232. Sildenafil reduced the infarct size in rabbits following
ischemia/reperfusion injury. This was abolished by the administration of 5hydroxydecanoate (5-HD), a mitochondrial ATP-sensitive potassium channel (mitoK+ATP)
blocker. These data suggest that sildenafil confers a preconditioning-like effect at
clinically relevant doses and that the cardioprotective mechanism is mediated by the
opening of mitoK+ATP.
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Subsequent studies revealed that sildenafil treated rat hearts had improved postischemic recovery of function, decreased incidence of ventricular fibrillation and decreased
area of infarction after being subject to global ischemia in Langendorff mode33.
Furthermore, 1400W, an iNOS inhibitor, blocked the cardioprotective effect of sildenafil.
These data demonstrate that the cardioprotective effect of sildenafil is mediated by NOdependent signaling.
It was possible that a hemodynamic effect rather than NO-mediated cell signaling
could have mediated cardioprotective effect of sildenafil. To demonstrate this protective
effect was independent of any vascular response, sildenafil was tested in isolated adult
mouse cardiomyocytes34. Simulated ischemia decreased the number of viable myocytes
with respect to non-ischemic controls. After eighteen hours of reoxygenation the rate of
cardiomyocyte apoptosis was increased. Pretreatment with sildenafil increased cell
viability and decreased cell loss by apoptosis compared to non-sildenafil treated cells.
This study demonstrated for the first time that PDE5 was expressed in murine
cardiomyocytes and that PKG, ERK, iNOS and GSK-3β are involved in the
cardioprotective mechanism of sildenafil35.
Sildenafil also has a powerful effect on myocardial infarction induced heart
failure36. Permanent coronary artery ligation is a more severe ischemic insult and leads to
the development of post-ischemic remodeling and heart failure. Sildenafil reduced infarct
size at 24 hours after permanent coronary artery occlusion. Treatment with sildenafil
decreased myocardial apoptosis at day 7 and day 28 and increased the BCL-2/BAX ratio
indicating an anti-apoptotic effect. Treatment with sildenafil also improved LV
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morphology and function, as determined by M-mode transthoracic cardiac
echocardiography. Specifically, sildenafil treated hearts had a decreased LV cavity and a
thicker anterior wall36. This indicates that less adverse remodeling had occurred with
sildenafil treated hearts, there was less wall thinning in the infarcted zone and there was
less chamber dilatation. Furthermore, sildenafil decreased the rate of aneurysmatic dilation
of the anterior wall. Sildenafil preserved cardiac functioning as evidenced by an increase
in fractional shortening compared to control.

Sildenafil attenuates cardiac hypertrophy
In 2005, Takimoto et al. demonstrated that chronic administration of sildenafil not
only prevented, but also reversed cardiac hypertrophy induced by transverse aortic
constriction37. In this study, the authors showed that sildenafil administration suppressed
chamber and myocyte hypertrophy, and improved in vivo heart function in mice exposed
to chronic pressure overload. Sildenafil also reversed pre-established hypertrophy induced
by pressure load while restoring chamber function to normal. cGMP catabolism by PDE5A increased in pressure-loaded hearts, and therefore inhibition of PDE-5A led to
restoration of cGMP signaling and activation of cGMP-dependent protein kinase (PKG).
These studies provided a new potential treatment strategy for cardiac hypertrophy and
remodeling.
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Cardiac Protection in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a progressive and fatal genetic disorder of
muscle degeneration. Patients with DMD lack dystrophin as a result of mutations in the Xlinked dystrophin gene. The loss of dystrophin leads to severe skeletal muscle pathologies
and cardiomyopathy, a delayed symptom of the disease that usually develops by the
second decade of life, with more than 90% of patients presenting clinical symptoms by 18
y of age38. Dystrophin-deficient mice (mdx mice) show cardiac dysfunction with decrease
in diastolic function followed by systolic dysfunction later in life. Chronic treatment with
sildenafil reduced functional deficits in the cardiac performance of aged mdx mice without
any effect on normal cardiac function in wild type controls 38. When sildenafil treatment
was started after cardiomyopathy had developed; the established symptoms were rapidly
reversed within a few days suggesting that PDE5 inhibitors may be a useful treatment
strategy for cardiomyopathy in DMD patients at early and late stages of the disease.

Sildenafil augments protection following heart transplantation
Based on the promising cardioprotective effect of sildenafil, Botha et al. further
investigated sildenafil-mediated cardioprotection in a rat model of heterotopic cardiac
transplantation39. Sildenafil citrate (0.7 mg/kg) was administered intravenously to the
donor 30 min before onset of ischemia or 5 min before reperfusion in the recipient. The in
situ cardioplegic arrest was followed by an ischemic time of 3 or 6 hr, transplantation and
blood reperfusion. In these studies, sildenafil preconditioning but not post-conditioning
significantly improved initial myocardial systolic and diastolic function after 3 hr of
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hypothermic cardioplegic arrest. The protective effect of sildenafil declined over a 3-hr
period of reperfusion along with overall myocardial function, no longer reaching statistical
significance at 3 hr. Interestingly, the protective effects of sildenafil were abolished by the
putative blocker of the mitochondrial ATP sensitive potassium channel, 5hydroxydecanoate, before sildenafil administration. These studies suggest that sildenafil
pretreatment augments myocardial functional recovery after an ischemic time relevant to
clinical cardiac transplantation.

Rationale and Specific Aims
Alcohol abuse has devastating effects on individuals and society, in that it often
leads to several medical disorders. Thus, it is critical to better understand the effects of
alcohol ingestion on altered organ function, and develop effective strategies to treat
alcohol-induced diseases. As reviewed above, alcohol damages the heart by several
mechanisms including oxidative stress14,17 and increasing apoptosis12,40,41. This leads to
left ventricular dysfunction7 and eventually heart failure9. Sildenafil and other PDE5
inhibitors exert powerful cardioprotective effect against ischemia-reperfusion injury
32,33,36,42-46

, heart failure 36, hypertrophy37 and cardiomyocyte necrosis/apoptosis33. NO

signaling plays a critical role in cardioprotection 47 as well alcohol-induced neurotoxicity25.

Based on this rationale, we therefore hypothesized that treatment with sildenafil
would attenuate cardiotoxicity associated with alcohol exposure through mechanisms
involving cGMP-dependent activation of PKG.
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Accordingly, the main goals of the present study are:

Aim 1: To demonstrate that PDE-5 inhibition with sildenafil attenuates
cardiomyocyte death following in vitro exposure of ethanol through activation of
PKG.

We propose that sildenafil will attenuate cardiomyocyte cell death in vitro following
exposure to ethanol through PKG activation. We will study the effect of sildenafil on
ethanol-induced necrosis and apoptosis in cardiomyocytes. PKG activity will be measured
in cardiomyocytes following treatment with ethanol and/or sildenafil. Strategies such as
gene knockdown of PKG Iα or its overexpression in cardiomyocytes would be utilized to
demonstrate the cause and effect relationship of this enzyme in protection against ethanol
toxicity.

Aim 2: To show that sildenafil protects against ethanol-induced cardiotoxicity
through opening of mitochondrial ATP-sensitive potassium channels, preservation of
mitochondrial integrity and decreased generation of ROS.

We propose that sildenafil-mediated cardioprotection against ethanol toxicity occurs via
the opening of mitoKatp channels, which is known to stabilize the mitochondrion 48
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We will show that treatment with sildenafil would preserve mitochondrial membrane
potential and decrease ROS production in cardiomycytes following exposure to ethanol.
We will also study the effect of 5-HD, a putative blocker of mitoKATP channels, on
sildenafil-mediated cardioprotection against ethanol in cardiomyocytes. The mitochondrial
membrane potential will be measured following ethanol treatment with/without sildenafil
as well as adenoviral knockdown and overexpression of PKG 1α.

Aim 3: To demonstrate that co-treatment of alcohol with sildenafil attenuates cardiac
dysfunction and decreases apoptosis in the heart.

We will demonstrate that co-treatment of alcohol with sildenafil attenuates ethanol-induced
cardiac dysfunction. Using an acute model of alcohol toxicity, we will measure cardiac
function in the Langendorff isolated perfused heart system.
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Figure 1. Mechanisms of Ethanol-Induced Cardiotoxicity. The development of
alcoholic cardiomyopathy begins with alcohol abuse. Ethanol directly, or indirectly
through acetaldehyde damages the myocardium by creating organelle dysfunction,
activating renin-angiotensin-aldosterone, altering myocyte protein expression, producing
oxidative damage or increasing apoptosis. The end result of each one of these pathways is
the death and functional loss of cardiomyocytes. This loss then leads to impaired cardiac
function. Continued alcohol abuse results in LV chamber dilation and heart failure and is
called alcoholic cardiomyopathy.

Materials and Methods
All animal studies were performed in accordance with the guidelines of the
National Institutes of Health “Guide for Care and Use of Laboratory Animals”. The
Institutional Animal Care and Use Committee of Virginia Commonwealth University
approved animal experimental protocols. All animals were housed in a 12:12 hour
light/dark cycle in a temperature-controlled room. Animals were fed standard rodent chow
(Harlan, Indianapolis, ID) and were provided water ad libitum.

Isolation of Primary Adult Rat Cardiomyocytes
Adult male rats were purchased from Harlan Sprague-Dawley. Each rat, weighing
approximately 300 grams, was anesthetized with sodium pentobarbital (100 mg/kg, i.p.).
Once deep surgical anesthesia was achieved, the thoracic cavity was opened via midline
sternotomy with Metzenbaum scissors. The superior and inferior vena cava were cut away
from the heart at the point which they enter the right atrium. The pulmonary vasculature
was trimmed from the heart in the same manner. The aorta was crosscut at a point distal to
the coronary arteries but proximal to the brachiocephalic artery. The heart was removed
from the chest; the aorta was quickly cannulated and attached to a Langendorff perfusion
apparatus. The aorta was secured to the perfusion apparatus with a single suture tied
circumferentially around the vessel. Care was taken to not obstruct coronary flow. The
aorta was retrogradely perfused (37° C) at a constant pressure of 55 mmHg for about 5
20
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minutes with Ca2+-free bicarbonate-based buffer containing (in mM): 120 NaCl, 5.4 KCl,
1.2 MgSO4, 1.2 NaH2PO4, 5.6 glucose, 20 NaHCO3, 10 2,3-butanedione monoxime, and 5
taurine, which was continuously bubbled with 95% O2 and 5% CO2. Collagenase type II
(Worthington, 0.5 mg/mL) and protease type XIV (0.02 mg/mL) was added to the
bicarbonate buffer. The enzymatic digestion proceeded for 15 minutes. 50 µM Ca2+ was
then added in to the enzyme solution and the heart was perfused for another 10-15 minutes.
The digested ventricular tissue was cut away from the atria and aorta. It was then cut into
chunks and placed into an Eppendorf tube containing the bicarbonate buffer. The
myocytes were mechanically dissociated by repeated gentle aspiration into a transfer
pipette. The cellular material was then passed through a 100 µm nylon cell strainer (BD
Bioscience) and centrifuged. The cell pellet was re-suspended in a three-step calcium
restoration procedure (i.e. 125, 250, 500 µM Ca2+). The freshly isolated cells were
suspended in Medium 199, containing 2 mM l-carnitine, 5 mM creatine, 5 mM taurine, 5
M glucose, 0.1 µM insulin, and 1% penicillin-streptomycin. The cells were plated on cell
culture dishes, which were pre-coated with 20 µg/mL mouse laminin in PBS for 1 hour.
The cardiomyocytes were cultured in the presence of 5% CO2 for 1 hour in a humidified
incubator at 37° C, which allowed cardiomyocytes to adhere to the dish surface prior to the
experimental protocol.

In vitro treatment Protocol
Myocyte cultures were randomly assigned into treatment groups (Figure 2). In
experiments using adenoviral genetic manipulations, adenoviral infection preceded
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ethanol/sildenafil treatment by 1 hour. Absolute ethanol (100%) was dissolved directly
into the medium to yield a final ethanol concentration of 100 mM. Stock solution of
sildenafil (obtained from Pfizer Inc) was prepared by dissolving the powder into sterile
H2O. This was further diluted into cell culture medium to yield a final concentration of 10
µM. This concentration was chosen because it conferred robust protection against necrosis
and apoptosis in isolated cardiomyocytes following simulated ischemia/reoxygenation as
reported previously 33. 5-HD was co-administered at 50 nM dissolved in media.

Knockdown of PKG1α with adenoviral shRNA
In order to knock down the expression of PKG1α we used siRNA targeting the
mouse cDNA of PKG Type I (GenBank accession number NM_001013833). This
corresponded to bases 1593 to 1611 and targeted the sequence 5’GAACAAAGGCCATGACATT-3’ (Dhammacon Research Inc., Lafayette, CO). A nontargeting scrambled RNA duplex siRNA control (NTSC, Dharmacon) containing 21nucleotide sequences demonstrating no homology to murine genes was also used as a
control for transfection. Transient transfections of duplex siRNAs (100 nm) were
performed in H9C2 cells using siPORT™ amine (Ambion). After 48 h, RNA was isolated
by Tri-Reagent (Molecular Research Center), and RT-PCR and quantitative real-time PCR
were performed. After confirming the significant reduction of PKG expression in H9C2
cells using this duplex siRNA targeting the mouse PKGI, shRNA expression vector for
PKG was constructed using the pSilencer™ adeno1.0-CMV system from Ambion
(Adenoviral siRNA expression Vector System). The hairpin siRNA oligonucleotide (55-
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mer) sequence 5′TCGAGGAACAAAGGCCATGACATTttcaagagaAATGTCATGGCCTTTGTTCAGA-3′
(mouse PKGI with sequence in capital letters and loop in lowercase italics) and its
antisense with XhoI and SpeI were synthesized, annealed, and subcloned into the pSilencer
adeno 1.0-CMV shuttle vector. HEK293 cells were transfected with linearized shRNA
vector together with adenoviral LacZ backbone to generate a recombinant adenovirus.as
described by Das et al 2008. Cells were infected with the virus at a concentration of 1 x
103 particles/cell.

Overexpression of PKG Iα
The adenoviral vector for overexpression of PKG Iα was constructed by cloning
the human PKG Iα as described 34. Cardiomyocytes were infected with adenoviral vector
containing PKG Iα of the catalytically inactive PKG IαK390A. Cells were infected with
the virus at a concentration of 1 x 103 particles/cell.

Assessment of Cardiomyocyte Necrosis:
Necrosis was assessed by trypan blue exclusion assay. Cardiomyocytes were
treated for 24 hours. At the end of the treatment protocol, 20 µl of 0.4% Trypan Blue
(Sigma-Aldrich) was added into the culture dish. After 5 min of equilibration, the cells
were counted under a Nikon inverted microscope using a 10X objective. Three
representative fields were chosen at random from each sample and then averaged.
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Necrosis was expressed as the percentage of trypan positive cells over the total number of
cells in each field of view.

Assessment of Cardiomyocyte Apoptosis
Cardiomyocyte apoptosis was assessed by terminal dUTP nick-end labeling
(TUNEL) using the ApoAlert™ DNA Fragmentation Assay (BD Bioscience, Palo Alto,
CA). Following the experimental protocol, cardiomyocytes were fixed in 4% formalin
dissolved in phosphate-buffered saline. TUNEL assay was then performed according to
manufacturer’s instructions. Following fixation, the cells were washed in a Coplin jar
containing room temperature PBS for five minutes. The cells were then permeabilized by
immersing them in pre-chilled 0.2% Triton X-100 in PBS for five minutes on ice. The cells
were again rinsed in PBS. Excess PBS was removed and the cells were covered in
equilibration buffer for 10 minutes. The equilibration buffer was then removed and 50 µl
TdT incubation buffer was placed on the cells. The tailing reaction was carried out in a
dark, humidified, 37° C for sixty minutes. Equilibration buffer was used in place of the
TdT reagent for a negative control. DNAase-I was applied for a positive control. The
tailing reaction of terminated by immersing the slides in a Coplin jar containing 2X SSC
and incubated in room temperature for fifteen minutes. Following the TUNEL assay the
slides were cover-slipped in Vectashield containing 4′, 6-diamidino-2-phenylindole
(DAPI) in order to visualize cell nuclei. The cardiomyocytes were examined on a Nikon
epifluorescent inverted microscope under a 10X objective. A FITC filter was used to
detect apoptotic cardiomyocyte nuclei. Apoptotic cells exhibit strong nuclear green
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fluorescence.

An ultraviolet filter was used to detected DAPI-stained cardiomyocyte

nuclei. Three representative fields were chosen at random from each sample and averaged.
Cardiomyocyte apoptosis was expressed as a function of TUNEL positive nuclei over total
cells per field.

Assessment of Cardiomyocyte PKG Activity
Cardiomyocyte PKG activity was measured with a CycLex cGMP-dependent
Protein Kinase Assay Kit (MLI International, Woburn MA). This PKG activity assay uses
a peroxidase coupled anti-phospho-G-kinase substrate threonine 68/119 monoclonal
antibody as a reporter. The colorimetric assay is performed in an ELISA format.
Cardiomyocytes were isolated, plated on 100x20 mm cell culture dishes and treated in
triplicate. Following the treatment protocol, the cardiomyocytes were scraped off of the
culture dish with a cell scraper and collected with the culture media into a 15 ml tube. The
samples were spun down and rinsed three times in phosphate-buffered saline. The cell
pellet was then placed in ice-cold lysis buffer (Cell Signaling) and homogenized. The
homogenate was centrifuged at 10,000 g for 10 minutes at 4° C. The supernatant was be
recovered as the total cellular protein. 100 µl of sample was transferred into a 96-well
plate provided in the kit and allowed to incubate for 30 minutes at 30 ° C. The wells of the
96-well plate were pre-coated recombinant PKG substrate. The wells were then washed
and then 100 µl of horseradish peroxidase conjugated anti-phospho-specific antibody was
added and allowed to incubate for 1 hour at room temperature. The wells were washed and
100 µl of substrate reagent was added. Absorbance was then measured at 450 nm.
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Absorbance was expressed in arbitrary units per µg of cell protein. Total protein
concentration was determined by Bradford assay.

Assessment of Cardiomyocyte Mitochondrial Membrane Potential (∆Ψm)
Mitochondrial membrane potential was assessed using 5,5’, 6,6’-tetrachloro-1, 1’,
33’- tetraethylbenzimidazole-carbocyanide iodine (JC-1, Biocarta, San Diego, CA). After
24 hour experimental incubation period, cells were incubated with 2 µg/ml JC-1 for 10
minutes at 37°C. The cells were washed in phosphate-buffered saline and examined under
a Nikon epifluorescent inverted microscope with a 10X objective. A dual-wave emission
filter was used to simultaneously record emission from both green and red emission
wavelengths. Red fluorescence represented the potential-dependent aggregation of JC-1 in
the mitochondria. Green fluorescence represents the monomeric form of the dye remaining
in the cytosol. The ratio of aggregate verses monomeric forms of JC-1 were counted.
Cardiomyocytes were counted from three representative fields per sample and averaged.
Mitochondrial membrane potential was expressed as a ratio of mitochondrial aggregate
(red emission) to the monomeric (green emission) form of JC-1.

Acute Model of Ethanol Toxicity
Adult male CD-1 mice, weighing approximately 30 grams were purchased from
Harlan. The acute model of ethanol toxicity used in this study was previously described13.
In brief, ethanol (3 g/kg/day) was administered by intraperitoneal (i.p.) injection for three
consecutive days (Figure 3). This dose was divided into two equal volumes and was
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administered once in the morning and then again in the evening. Mice were randomized
into one of four groups. Group 1 received saline only and served as a control. Group 2
received ethanol treatment (3.0 g/kg/day i.p.). Group 3 received sildenafil (0.7 mg/kg i.p.).
Group 4 received both ethanol (3.0 g/kg/day i.p.) and sildenafil (0.7 mg/kg i.p.). This dose
of sildenafil was chosen because it simulates a 70 kg male taking a 100 mg tablet of
sildenafil with 49% bioavailability of PO administration (100 mg / 70 kg) x 49% = 0.70
mg/kg). Each group received the same volume of intraperitoneal injection each day.

Assessment of Cardiac Function
Following three treatment days, mice were anesthetized with sodium pentobarbital
(100 mg/kg). Once deep surgical anesthesia was achieved, the thoracic cavity was opened
via midline sternotomy with Metzenbaum scissors. The superior and inferior vena cava
were cut away from the right atrium and the pulmonary vasculature was cut away from the
heart in the same manner. The aorta was cross cut at a point distal to the coronary arteries
but proximal to the brachiocephalic artery. The heart was removed from the chest and
placed into a small dish containing ice-cold Krebs-Henseleit buffer. The aorta was quickly
cannulated and mounted onto a Langendorff perfusion system. The aorta was secured to
the perfusion apparatus with a single suture tied circumferentially around the vessel. Care
was taken to not obstruct coronary flow. The aorta was retrogradely perfused (37° C) at a
constant pressure of 55 mmHg with Krebs-Henseleit buffer containing (in mM): NaCl 118,
NaHCO3 24, CaCl2, 2.5, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, Glucose 11, EDTA 0.5. The
perfusion solution was continuously gassed with 95% O2 + 5% CO2 and warmed by a
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warming bath. The heart temperature was continuously monitored and maintained at 37 °C
throughout the experiment. After the heart began to spontaneously contract, a forcedisplacement transducer (Grass, Model FT03) was attached to the cardiac apex with a No.
5 surgical thread and a metal hook. The resting tension of the isolated heart was adjusted to
0.30 grams. Ventricular developed force was recorded with a Beckman R-5llA polygraph
connected to the force transducer. Prior to each experiment the force transducer was
calibrated. The heart was allowed to stabilize for 30 minutes, at which point cardiac
functional parameters were recorded. Rate force product, an index of myocardial oxygen
demand and workload, was calculated by multiplying developed force with the heart rate.
Coronary flow rate was measured by timed collecting the coronary artery effluent for one
minute. Following functional analysis the hearts were placed in 10% formalin or snapfrozen in liquid nitrogen.

Assessment of Myocardial Apoptosis
Following functional analysis and fixation in 10% formalin, the heart was rinsed
and PBS. The tissue was dehydrated and embedded in paraffin. The tissue was sectioned
in the transverse plane in 5 µm sections and placed on a glass microscope slide. The tissue
was de-parafinized in xylene bath and re-hydrated. TUNEL assay was then performed
according to manufacturer’s instructions. The heart sections were then permeabilized by
immersing them in pre-chilled 0.2% Triton X-100 in PBS for five minutes on ice. The
sections were rinsed in PBS. Excess PBS was removed and the sections were covered in
equilibration buffer for 10 minutes. This was followed by incubation with 50 µl TdT
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buffer. The tailing reaction was carried out in the dark at 37° C for 60 minutes. For a
negative control equilibration buffer was used in place of the TdT reagent and for a
positive control DNAase-I was applied. The tailing reaction was terminated by immersing
the slides in a Coplin jar containing 2X SSC and incubated in room temperature for fifteen
minutes. Following the TUNEL assay the slides were cover-slipped in Vectashield
containing 4′, 6-diamidino-2-phenylindole (DAPI) in order to visualize cell nuclei. The
myocardial sections were examined on a Nikon epifluorescent microscope under a 10X
objective. A FITC filter was used to detect apoptotic cardiomyocyte nuclei. Apoptotic
cells exhibit strong nuclear green fluorescence.

An ultraviolet filter was used to detected

DAPI-stained myocardial nuclei. Three representative fields were chosen at random from
each sample and averaged. Myocardial apoptosis was expressed as an apoptotic index (AI).
In this system one is not clearly able to differentiate one myocardial cell from another and
cardiac cells are multinucleate. Therefore AI is a function of TUNEL positive nuclei over
total nuclei cells per field.

Assessment of Myocardial PKG Activity
Myocardial PKG activity was measured with a CycLex cGMP-dependent Protein
Kinase Assay Kit (MLI International, Woburn MA). This PKG activity assay uses a
peroxidase coupled anti-phospho-G-kinase substrate threonine 68/119 monoclonal
antibody as a reporter. The colormetric assay is performed in an ELISA format. Whole
hearts were snap-frozen in liquid nitrogen. Frozen hearts were then crushed in a clean
mortar and pestle with liquid nitrogen. The myocardial powder was then placed in ice-cold
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lysis buffer (Cell Signaling) and homogenized on ice. The homogenate was centrifuged at
10,000 g for 10 minutes at 4° C. The supernatant was recovered as the total cellular
protein. 100 µl of sample was transferred into a 96-well plate provided in the kit and
allowed to incubate for 30 minutes at 30 ° C. The wells of the 96-well plate were precoated recombinant PKG substrate. The wells were then washed and then 100 µl of horse
radish peroxidase conjugated anti-phospho-specific antibody was added and allowed to
incubate for 1 hour at room temperature. The wells were washed and 100 µl of substrate
reagent was added. Absorbance was then measured at 450 nm. Absorbance was expressed
in arbitrary units per µg of cell protein. Total protein concentration was determined by
Bradford assay.

Statistics
Data was expressed mean ± standard error of the mean. Difference between groups
was analyzed with a one-way ANOVA with a Bonferroni post-hoc. P < 0.05 was
considered statistically significant.
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Figure 2. In Vitro Model of Ethanol-induced Cardiomyocyte Toxicity. Adult rat
cardiomyocytes were isolated by enzymatic digestion with collagenase and plated in
calcium-free bicarbonate buffer. This technique yields a culture of approximately 95%
rod-shaped myocytes. These cells were then subjected to experimental procedures to
include adenoviral gene manipulation, ethanol treatment and/or sildenafil treatment. At 24
hours of treatment trypan blue exclusion assay, JC-1 fluorescence, DCF fluorescence, and
PKG activity were measured. At 48 hours TUNEL assay was performed.
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Figure 3. Acute Model of Ethanol-induced Cardiotoxicity. Mice were given ethanol 1.5
g/kg twice daily by intraperitoneal injection for three consecutive days (3.0 g/kg/day).
Sildenafil was given to certain groups at a dose of 0.7 mg/kg also by intraperitoneal
injection. On the fourth day the animals were sacrificed and cardiac function was
measured in Langendorff mode. In addition, apoptosis was measured by TUNEL assay and
PKG activity was measured using CycLex cGMP-dependent Protein Kinase Assay Kit .
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Results

The effect of sildenafil on cardiomyocyte cell death

Central to the development of ACM appears to be cardiomyocyte loss 10.
Cardiomyocytes may die either by necrosis or apoptosis. Necrosis is commonly seen
during myocardial infarction and ischemic cardiomyopathy, but is rarely observed in nonischemic dilated cardiomyopathy. In the present study, we tested the hypothesis that PDE5 inhibition with sildenafil attenuates cardiomyocyte death through activation of PKG in
an in vitro model of ethanol toxicity. To accomplish this aim, primary adult rat
cardiomyocytes were isolated and then treated with 100 mM ethanol ± 10 µM sildenafil for
24 hours. Necrosis was assessed by Trypan Blue exclusion assay and apoptosis was
assessed by TUNEL as described in the Methods. Treatment of cardiomyocytes with
ethanol for 24 hours increased the rate of necrotic cell death compared to control (Figure
4). Co-treatment with 10 µM sildenafil attenuated ethanol-induced increased cell death (P
< 0.001 vs. ethanol alone). Sildenafil alone had no significant effect on cardiomyocyte
necrosis compared to control. Furthermore, ethanol treated cardiomyocytes displayed an
increased apoptotic rate compared to control (Figure 5, P < 0.01). Co-treatment with
sildenafil attenuated the ethanol-induced cardiomyocyte apoptosis (P < 0.01 vs. ethanol
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alone). There was no significant effect of sildenafil on cardiomyocyte apoptosis when
compared to the control untreated group (P > 0.05).

Protein Kinase G activity

Protein Kinase G (PKG) or cGMP-dependent protein kinase is a serine/threonine
specific protein kinase that is one of the major intracellular receptors for cGMP. This
serine/threonine protein kinase has two isozymes (type I and type II; i.e. PKGI and PKGII)
that are presented in eukaryotic cells. The N terminus of PKGI is encoded by two
alternatively spliced exons that produce the isoforms, α and β49-51. PKGIα is mainly found
in lung, heart, platelets, and cerebellum, whereas PKGIβ is highly expressed with PKGIα
in smooth muscles of uterus, vessels, intestine, and trachea 52,53. More importantly, the
activation of PKG phosphorylates numerous intracellular proteins that in turn regulate
many important physiological functions such as control of vascular tone, cell
differentiation and proliferation, and platelet aggregation 52. Previous studies from this lab
have demonstrated that sildenafil has a potent cardioprotective effect against
ischemia/reperfusion injury 32,36,44-46. To determine whether the protective effect of
sildenafil against necrosis and apoptosis occurs through a PKG-dependent mechanism, we
measured PKG activity in cardiomyocytes exposed to ethanol in presence and absence of
sildenafil. The results show that exposure of cardiomyocytes to 10 µM sildenafil increased
the activity of PKG compared to control myocytes (Figure 6, P < 0.05). The presence of
ethanol did not significantly effect PKG activation by sildenafil when compared to
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sildenafil treated cardiomyocytes. Ethanol treatment consistently displayed a trend toward
increasing PKG activity, but it was not statistically significant from control.

Effect of PKG Iα knockdown on Sildenafil-mediated protection against ethanol
toxicity
Previous studies have shown that pharmacological inhibitors of PKG blocked
preconditioning of cardiomyocytes 54,55. Moreover, the PKG inhibitors KT 5823,
guanosine 3’,5’ cyclic monophosphorothioate, 8-(4-chloro-phenylthio) and DT-2 blocked
the anti-necrotic and anti-apoptotic effect of sildenafil 34. Knockdown of PKG with siRNA
has also been shown to abolish the cardioprotective effect of sildenafil against ischemia
reperfusion injury. In order to demonstrate the cause and effect of PKG activation in
sildenafil-induced protection against ethanol toxicity, siRNA was used to knock down
PKG 1α. Cardiomyocytes were infected with adenovirus containing either scrambled
siRNA (shControl) or siRNA directed against PKG Iα (shPKG). Adenoviral infection with
shControl or shPKG had no effect on cardiomyocyte necrosis or apoptosis (Figures 7 and
8, respectively). shControl + Sildenafil + Ethanol demonstrated cardioprotection and was
not significantly different from shControl + Sildenafil with respect to necrotic and
apoptotic cell death. Knockdown of PKG blocked the cardioprotective effect of sildenafil
against ethanol toxicity. This was evident by an increase rate of necrosis (P < 0.01 vs.
shPKG + Sildenafil) and apoptosis (P < 0.001 vs. shPKG + Sildenafil).

Effect of PKG Iα overexpression on ethanol-mediated necrosis and apoptosis

36

Previous studies from the laboratory have shown that overexpression of PKG Iα,
even in the absence of any preconditioning stimulus, conferred a cardioprotective effect 34.
In these studies, adult rat cardiomyocytes were infected with adenoviral vectors containing
PKGIα or catalytically inactive mutant PKGIαK390A prior to simulated ischemia and
reoxygenation. PKGIα overexpression resulted in significant decrease in necrosis and
apoptosis following simulated ischemia and reoxygenation34. To examine the effect of
PKG Iα in attenuation of ethanol-induced cardiotoxicity, adult rat cardiomyocytes were
infected with adenovirus to overexpress PKG Iα. Over-expression of PKG1α reduced
ethanol-induced necrosis (Figure 9, P < 0.01) and apoptosis (Figure 10, P < 0.05) as
compared to the cardiomyocytes infected with the catalytically inactive mutant
PKGIαK390A inactive mutant. Adenoviral infection and overexpression of PKG Iα had
no significant effect on cardiomyocyte necrosis or apoptosis (Figure 9 and 10,
respectively).

Assessment of Mitochondrial Membrane Potential (∆Ψm)
In the present study, we used the cationic lipophilic probe JC-1 to assess the
mitochondrial membrane potential (ΔΨm) 56-58. The mitochondria of non-apoptotic cells
appear in red following the aggregation of the JC-1 reagent, which emits red fluorescence
at 590 nm. In contrast, in the apoptotic or dead cells the JC-1 dye remained in its
monomeric form, thereby emitting relatively more green fluorescence JC-1 exhibits a
potential dependent accumulation in the mitochondria and as such exhibits red
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fluorescence at approximately 590 nm. When mitochondria are depolarized there is a shift
in the fluorescence to green at approximately 529 nm. Exposure of adult rat
cardiomyocytes to 100 mM ethanol for 24 hours resulted in dissipation ∆Ψm as illustrated
by JC-1 immunofluorescence (Figure 11, P < 0.001 vs. control). Cardiomyocytes that
were co-treated with 10 µM sildenafil and ethanol preserved the mitochondrial membrane
potential (P < 0.001 vs. ethanol alone). Sildenafil alone had no significant effect on ∆Ψm
compared to control. Knockdown of PKG with siRNA blocked sildenafil-mediated
preservation of ∆Ψm (Figure 12, P < 0.0), while overexpression of PKG1α preserved ∆Ψm
(Figure 13). Adenoviral control and mutant PKG had no effect on ∆Ψm.

Role of mitochondrial ATP-sensitive K+ channel in Protection against Ethanol
Toxicity with Sildenafil

Opening of the mitochondrial ATP-sensitive K+ (mitoKATP) channel plays an
important role in ischemic as well as pharmacological preconditioning with sildenafil in
the heart32,59. Opening the mitoKATP channel partially compensates the membrane
potential, which enables additional protons to be pumped out to form a H+ electrochemical
gradient for both ATP synthesis and Ca2+ transport60. Opening of this channel allows the
cardiomyocyte to regulate intracellular calcium levels as well as cell swelling. This
preserves mitochondrial functioning and prevents initiation of apoptosis. Sarcolemmal
channels are the premier sensors of the energy state of the myocyte and, when activated,
shorten or interrupt the action potential 61. 5-Hydroxydedecanoate (5-HD) is a putative
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blocker of mitochondrial mitoKATP channel which has been shown to block the protective
effect of ischemic preconditioning in the heart 62. To determine if sildenafil protects
cardiomyocytes against ethanol toxicity through opening of mitoKATP channel, adult rat
cardiomyocytes were treated with ethanol in the presence of 5-HD. This group displayed a
higher rate of necrosis compared to ethanol alone (Figure 14, P < 0.001). When co-treated
with ethanol, sildenafil and 5-HD, an increased rate of necrosis was observed as compared
to ethanol and sildenafil (P < 0.001). 5-HD blocked sildenafil-mediated preservation of the
mitochondrial membrane potential in the presence of ethanol as well (Figure 15, P < 0.01).
This loss of mitochondrial membrane potential was not statistically different from ethanol
and 5-HD (P > 0.05).

Assessment of ROS production
As reviewed in the above text, oxidative stress plays a role in the development of
cardiotoxicity leading to ACM. The oxidation of both ethanol and acetaldehyde lead to
free radical production (35, 47).

The accumulation of ROS generated by the metabolism

of ethanol and acetaldehyde, coupled with the depletion of oxidant defenses, creates an
environment capable of producing cellular damage. In the present study, we investigated
the role of sildenafil in attenuation of ROS generation in cardiomyocytes following
exposure to ethanol. The adult rat cardiomyocytes were incubated with ethanol in the
presence and absence of ethanol.

ROS production was measured by DCF fluorescence as

described in the Methods. Figure 16 shows that ethanol treatment caused significant
increase in ROS production, which is clearly indicated by enhanced intensity of DCF

39
fluorescence (P < 0.001 vs. control). Co-treatment with sildenafil and ethanol attenuated
the ethanol-induced ROS production. Sildenafil alone had no effect on ROS production as
compared with control.

Ethanol and Cardiac Dysfunction

To further demonstrate the effect of sildenafil in protecting against ethanol
cardiotoxicity in vivo, we treated adult male CD-1 mice with ethanol (3 g/kg) ± sildenafil
(0.7 mg/kg) by i.p. injection for three consecutive days. On the fourth day, the animals
were sacrificed, the hearts isolated and perfused in Langendorff mode and cardiac function
was measured. Coronary flow rate was determined by a timed collection of the coronary
artery effluent. Ethanol decreased the rate force product (Figure 17A, P < 0.01 vs. control).
Co-treatment with sildenafil attenuated cardiac dysfunction (P < 0.01 vs. ethanol alone).
Sildenafil alone had no effect on the rate force product compared to control. Furthermore,
co-administration of 5-HD displayed decrease the rate force product as compared to
ethanol and sildenafil treated group (P < 0.01 vs. ethanol + sildenafil). There was no
significant difference in heart rates between any groups (Figure 17 B), nor was there any
difference in coronary flow rates (Figure 17 C).

Myocardial Apoptosis
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Acute ethanol toxicity has been shown to increase myocardial apoptosis 13. Such a
loss of cells represents an early phase of the progression of alcoholic cardiomyopathy.
Thus, preventing cell loss during initial stages of ethanol toxicity would represent
significant advancement in prevention alcohol-related cardiac disease.

Accordingly, we

hypothesized that sildenafil will decrease the rate of myocardial apoptosis in response to
acute ethanol toxicity. Our results show that ethanol administration in mice caused
myocardial apoptosis as indicated by the increase in TUNEL positive nuclei (Figure 18, P
< 0.001 vs. control). The administration of sildenafil attenuated the ethanol-induced
increase in the myocardial apoptotic index (P < 0.001 vs. ethanol alone). Sildenafil alone
had no significant effect on myocardial apoptosis compared to control.

Myocardial PKG Activity
Sildenafil administration increased myocardial PKG activity in both sildenafil and
sildenafil + ethanol groups (Figure 19, P < 0.01 vs. control). The administration of ethanol
did not affect PKG activity in ethanol alone compared to control or ethanol + sildenafil
compared to sildenafil alone.
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A.

B.

Figure 4. Representative images of cardiomyocytes and quantitative data showing the
effect of sildenafil pretreatment on ethanol-induced toxicity. A. Color photomicrograph
with a 10x objective. Cardiomyocytes stained with trypan blue. Blue staining is indicative
of loss of cell membrane integrity and thus necrotic cell death. Note that the number of
trypan blue positive cells were significantly reduced in sildenafil+ethanol-treated myocytes
as compared to ethanol alone. B. Quantitative results of anti-necrotic protection of
sildenafil against ethanol toxicity
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B.

Figure 5. Effect of sildenafil on inhibition of apoptosis in cardiomyocytes following
exposure to ethanol. A. TUNEL assay images showing green punctate dots indicative of
fragmented nuclei associated with apoptosis. A significant number of cardiomyocytes
underwent apoptosis (i.e. TUNEL-positive) with EtOH exposure whereas sildenafil
pretreatment reduced TUNEL-positive nuclei (EtOH+sil). B. Ethanol increased the rate of
cardiomyocyte apoptosis. Sildenafil decreased the ethanol-induced increase in apoptosis.

43

Figure 6. PKG Activity in Cardiomyocytes. Treatment with sildenafil increased PKG
activity. Ethanol administration did not significantly affect PKG activation.
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Figure 7. Effect of PKG1α silencing (knockdown) on anti-necrotic effects of sildenafil
against ethanol toxicity in adult rat cardiomyocytes. Adenoviral knockdown of PKG Iα
increased the number of trypan blue positive cardiomyocytes treated with sildenafil and
ethanol (sPKG+SIL+EtOH) as compared to the corresponding control virus infected cells
(shControl+SIL+EtOH). There was no significant difference in the number of trypan blue
positive cells between the shControl+SIL and shPKG+SIL treated groups. As expected,
EtOH significantly increased number of trypan blue positive cells as compared to nontreated control cardiomyocytes.

H
O
Et
+

Et
+

SI

SI
L

L

+

G

sh
PK

G

+

on
tr
ol
sh
C

O
H

l
+

Si

Si
l
+

on
tr
ol

sh
PK

O

H

*

sh
C

C

* P <0.001 vs all other groups
N=4
*

Et

11
10
9
8
7
6
5
4
3
2
1
0

on
tr
ol

Apoptotic Rate
(% of Total Cells)

45

Figure 8. Effect of PKG1α silencing (knockdown) on anti-apoptotic effects of
sildenafil against ethanol toxicity in adult rat cardiomyocytes. Adenoviral knockdown
of PKG Iα increased the number of TUNEL positive cardiomyocytes treated with sildenafil
and ethanol (sPKG+SIL+EtOH) as compared to the corresponding control virus infected
cells (shControl+SIL+EtOH). There was no significant difference in the number of
TUNEL positive cells between the shControl+SIL and shPKG+SIL treated groups. As
expected, EtOH significantly increased number of TUNEL positive cells as compared to
non-treated control cardiomyocytes.
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Figure 9. PKG1α inhibits ethanol-induced necrosis in adult rat cardiomyocytes.
Adenoviral overexpression of PKG Iα reduced the number of trypan blue positive necrotic
cardiomyocytes following treatment with ethanol (adPKG1α+EtOH) as compared to the
ethanol (EtOH) and overexpression of corresponding catalytically inactive PKGIαK390A
(adMut+EtOH) groups. There was no significant difference in the number of trypan blue
positive cells between the control, adPKG1α and adMut groups
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Figure 10. PKG1α inhibits ethanol-induced apoptosis in adult rat cardiomyocytes.
Adenoviral overexpression of PKG Iα reduced the number of TUNEL positive
cardiomyocytes following treatment with ethanol (adPKG1α+EtOH) as compared to the
ethanol (EtOH) and overexpression of corresponding catalytically inactive PKGIαK390A
(adMut+EtOH) groups. There was no significant difference in the number of TUNEL
positive cells between the control, adPKG1α and adMut groups.
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Figure 11. Effect of sildenafil on preservation of mitochondrial membrane potential
(∆Ψm) in cardiomyocytes. A. Color micrograph with a 10x objective. JC-1 fluorescence.
Isolated rat cardiomyocytes were loaded with cationic lipophilic probe JC-1. Note the
predominant aggregate (nonapoptotic) mitochondria (in red/orange color) in control,
ethanol+sildenafil (EtOH+Sil) and sildenafil alone (Sil) as compared to the ethanol alone
(EtOH) treated group which shows green fluorescence indicating the monomeric form of
JC-1 and a disruption of mitochondrial membrane potential. B. Quantification of JC-1
aggregate/monomer ratio, which shows sildenafil (Sil) increased significantly the ratio (i.e.
lesser lost in ΔΨm) as compared with the untreated ethanol group. No significant
difference in the ΔΨm was observed between the control, EtOH+Sil and Sil groups.
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A.

B.

Figure 12. Role of PKG1α on sildenafil-induced preservation of mitochondrial
membrane potential (∆Ψm) following ethanol exposure of cardiomyocytes. Isolated
rat cardiomyocytes were loaded with cationic lipophilic probe JC-1. Note the green
fluorescence indicating the monomeric form of JC-1 and a disruption of ∆Ψm in the
ethanol (EtOH) and sildenafil plus ethanol treatment in cardiomyocytes with adenoviral
knockdown of PKG Iα (shPKG+Sil+EtOH) as compared with the predominant aggregate
(nonapoptotic) mitochondria (in red/orange color) in control, control adenovirus infected
cells (shControl), PKG1α silencing (knockdown) adenovirus (shPKG), control adenovirus
with sildenafil (shContol+Sil), control adenovirus with sildenafil and ethanol
(shContol+Sil+EtOH) treated groups. B. Quantification of JC-1 aggregate/monomer ratio,
which shows the same trend of ∆Ψm as in stated in A.
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Figure 13. Direct effect of PKG1α in sildenafil-induced preservation of mitochondrial
membrane potential (∆Ψm) in cardiomyocytes following exposure to ethanol.
Adenoviral overexpression of PKG Iα preserved ∆Ψm cardiomyocytes following treatment
with ethanol (adPKG1α+EtOH) as compared to the ethanol (EtOH) and overexpression of
corresponding catalytically inactive PKGIαK390A (adMut+EtOH) groups. There was no
significant difference in the ∆Ψm between the control, adPKG1α and adMut groups.
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Figure 14. Role of MitoKATP channels in Sildenafil-induced protection against
Cardiomyocyte toxicity. Note that the number of trypan blue positive cells are
significantly with 5-hydroxydecanoate (5-HD) following treatment with ethanol +
sildenafil (EtOH+Sil+5-HD) as compared with ethanol+sildenafil-treated myocytes. It is
also noteworthy that trypan blue positive cells were significantly higher following
treatment with ethanol + as compared to ethanol alone suggesting pro-necrotic effect of 5HD.
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Figure 15. Effect of 5-hydroxydecanoate (5-HD) on loss of mitochondrial membrane
potential (∆Ψm) following treatment with sildenafil and ethanol in cardiomyocytes.
on preservation of in cardiomyocytes. Note that co-treatment of ethanol (Et-OH),
sildenafil (Sil) and 5-HD caused loss of ∆Ψm as compared to the untreated control,
ethanol+sildenafil (EtOH+Sil) and sildenafil (Sil) treated groups. 5-HD alone also caused
significant loss of ∆Ψm. The ∆Ψm between ethanol (EtOH), ethanol+5-HD (EtOH+5-HD)
and ethanol+sildenafil+5HD (EtOH+Sil+5-HD) treated groups was not significantly
different.
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Figure 16. Sildenafil inhibits reactive oxygen species (ROS) generation following
ethanol treatment in cardiomyocytes. Note that ethanol treatment causes an increase in
cardiomyocyte ROS production as indicated by increase in DCF fluorescence. Treatment
with sildenafil blunted ethanol-induced increase in ROS (EtOH+Sil).
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A.

B.
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C.

Figure 17. Sildenafil preserves cardiac function via opening of mitoKATP channels in
ethanol treated mice. A. Rate force product. Note that treatment with ethanol (3.0
g.kg/day) decreased the rate-force product as compared to the control mice. Co-treatment
with sildenafil (0.7 mg/kg) preserved cardiac function (EtOH+Sil). 5-HD blocked the
sildenafil-induced preservation of function. B. Heart rate. There was no significant
difference between the groups. C. Coronary Flow. No significant difference in the
coronary flow rate was observed between the groups.

56
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Figure 18. Effect of sildenafil on inhibition of apoptosis in the heart following
following treatment with ethanol. A. TUNEL assay images. White arrows indicate
apoptotic nuclei indicative of fragmented nuclei associated with apoptosis. A significant
number of cardiomyocytes underwent apoptosis (i.e. TUNEL-positive) with EtOH
treatment whereas sildenafil pretreatment reduced TUNEL-positive nuclei (EtOH+sil). B.
Bar diagram showing quantitative data on apoptosis.
Ethanol increased the rate of
myocardial apoptosis. Co-treatment with sildenafil attenuated the ethanol-induced
increased in myocardial apoptosis.
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Figure 19. PKG activity in heart. Treatment with sildenafil increased PKG activity.
Ethanol administration did not significantly affect PKG activation.
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Discussion

Excessive chronic alcohol ingestion causes both histopathologic and functional
changes in multiple organs, especially in the liver, heart, and pancreas, and can result in
serious or even fatal illness. Chronic, excessive alcohol consumption has been reported to
be the most frequent identifiable cause of heart muscle disease 63 and has been shown to
decrease the contractility of heart muscle in both animals and humans 64. Its classical
clinical cardiac consequence is a dilated cardiomyopathy, which can lead to congestive
heart failure and even to death. There exist no unique identifying features that set
alcoholic cardiomyopathy apart from other causes of heart failure. The diagnosis is further
complicated by the frequent presence of other risk factors for cardiomyopathy. History is
key, as is a definite lack of other inciting factors, such as certain prescribed or nonprescribed drugs (e.g. doxorubicin, cocaine) or ischemic heart disease, to strengthening the
diagnosis, which remains one of exclusion. When clinically manifest, alcoholic
cardiomyopathy demonstrates 4-chamber dilation, low cardiac output, and normal or
decreased left ventricular wall thickness. Clinical stigmata of heart failure, such as a third
heart sound, elevated jugular venous pulse, and cardiomegaly with or without rales, may
be seen, especially in decompensated states. The coexistence of liver disease due to
cirrhosis may give rise to diagnostic confusion when the picture may be less
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straightforward. The association of supraventricular arrhythmias with heavy alcohol intake
(holiday heart syndrome) and an association with sudden cardiac death are further
complications of alcohol abuse in alcoholic cardiomyopathy patients 65,66. Based on the
observations of Fauchier et al 67, the causes of death in patients with alcoholic
cardiomyopathy are similar to those with idiopathic cardiomyopathy: progressive chronic
heart failure and sudden cardiac death. Moreover, alcoholics with simultaneous
cardiomyopathy and cirrhosis carry a worse prognosis68.
Many cellular and molecular mechanisms of injury have been proposed as the
basis for alcoholic cardiomyopathy, including apoptosis 12, mitochondrial dysfunction 13,
acetaldehyde protein adduct formation 69 and oxidant stress 70.

Medical therapy available for alcoholic cardiomyopathy is no different from that
for other etiologies of heart failure, except it should include abstinence from alcohol as a
cornerstone 71,72. Survival is poor in those who continue to drink heavily, with 4-year
mortality levels close to 50%. One should follow the heart failure guidelines, such as those
adopted by the European Society of Cardiology or the American College of
Cardiology/American Heart Association referred to earlier, that incorporate the use of
certain beta-blockers and ACE inhibitors or angiotensin receptor blockers (ARBs).
Diuretics and digitalis can be used in the management of symptomatic alcoholic
cardiomyopathy patients. Some of these patients may have coexisting nutritional
deficiencies (vitamins, minerals such as selenium or zinc), which may need correction as
well, because they can independently worsen outcomes or hamper attempts at treatment.
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Sildenafil is a selective potent inhibitor of PDE5 (a cGMP-specific isoform of
PDE), which promotes increase in cGMP in vascular smooth muscle cells by preventing its
breakdown with PDE5 73. In the present study, we investigated the potential role of
sildenafil in attenuating the alcohol-induced cardiotoxic effect in cardiomyocytes and
intact heart. This approach was based on strong rationale provided by several basic
science studies demonstrating the cardioprotective effect of sildenafil and other PDE-5
inhibitors in a number of clinical scenarios including ischemia/reperfusion injury,
myocardial infarction, heart transplantation, cardiac hypertrophy, heart failure,
doxorubicin-induced cardiotoxicity, Duchenne muscular dystrophy and stem cell
preconditioning 29,30,43. Our results show that treatment of adult cardiomyocytes with with
100 mM ethanol increased the rate of necrotic cell death compared to control (Figure 4).
Co-treatment with sildenafil attenuated ethanol-induced increased cell death.
Furthermore, ethanol treated cardiomyocytes displayed an increased apoptotic rate
compared to the control (Figure 5) and co-treatment with sildenafil attenuated the ethanolinduced cardiomyocyte apoptosis as well.

Moreover, we demonstrated that the protective

effect of sildenafil against ethanol cardiotoxicity was attributed to the PKG-dependent
signaling, preservation of mitochondrial membrane potential, opening of mitochondrial
ATP-sensitive K+channels and decreased generation of ROS. Furthermore, our results
showed that sildenafil co-treatment with ethanol preserved cardiac function in the isolated
perfused heart and inhibited apoptosis as compared to ethanol treated mice. Taken
together, these results provide strong evidence that sildenafil has protective effect against
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ethanol-induced toxicity in adult cardiomyocytes in vitro and preservation of cardiac
function in the intact heart. Moreover, these results on sildenafil-induced anti-apoptotic
effect may have potential therapeutic ramification in the treatment of alcohol-induced
cardiomyopathy.

Like many other cardiovascular diseases such as atherosclerosis, myocardial
ischemia and reperfusion injury, and diabetic cardiomyopathy, apoptosis plays a pivotal
role in the pathogenesis of alcoholic cardiomyopathy 74. The up-regulated expression of
caspase-3 and Bax, as well as increased TUNEL positive cells and caspase-3 activity
depicted the presence of a global myocardial apoptosis following chronic ethanol intake 75.
Moreover, ethanol intake was found to promote phosphorylation of JNK and ASK-1, two
pivotal pro-apoptotic signaling molecules. Over time, apoptosis leads to structural
changes that are maladaptive and will eventually lead to heart failure. The present study
demonstrated significant in increase in necrosis as well as apoptosis following acute
treatment with ethanol, which was significantly attenuated by co-treatment with sildenafil
and ethanol. Also, sildenafil decreased ethanol-induced apoptosis in the intact heart.
These data further support previous results showing inhibition of necrosis and apoptosis by
sildenafil in murine cardiomyocytes subjected to simulated ischemia and reoxygenation,
attenuation of apoptosis following doxorubicin and ischemic cardiomyopathy through
upregulation of Bcl2/Bax ratio and inhibition of caspase-336,76. It is notable that the
protective dose of sildenafil used in the present study was 10 µM (∼6.9 µg/ml), which is in
the physiological range of its therapy in patients.
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PDE-5 is the major enzyme that is responsible for catalytic break-down of cGMP in
the vascular smooth muscle cells 77, its inhibition leads to increased cGMP accumulation
and subsequent activation of PKG. Therefore, we evaluated the role of PKG in sildenafilinduced protection against alcohol toxicity. We used two complimentary approaches to
accomplish this goal: (a) siRNA directed against PKG Iα (shPKG) to knock down PKG
1α, which is mainly found in lung, heart, platelets, and cerebellum; (b) adenoviral vectors
containing PKGIα to overexpress this protein in cardiomyocytes. Cardiomyocytes were
infected with adenovirus containing either scrambled siRNA (shControl) or siRNA
directed against PKG Iα (shPKG). Knockdown of PKG blocked the cardioprotective effect
of sildenafil against ethanol toxicity. This was evident by an increase rate of necrosis and
apoptosis (Figure 7 & 8). Furthermore, PKGIα overexpression (in the absence of
sildenafil) also resulted in significant decrease in necrosis and apoptosis in cardiomyocytes
treated with ethanol as compared to the cardiomyocytes infected with the catalytically
inactive mutant PKGIαK390A (Figures 9 & 10). These highly complementary approaches
conclusively demonstrate that PKG is mediator of the protective effect of sildenafil against
alcohol-induced toxicity in cardiomyocytes.

It is well known that apoptosis is a cellular process involving a genetically programmed
series of events leading to the death of a cell.

During this process, several key events

occur in mitochondria including the release of caspase activators including cytochrome c,
changes in electron transport and loss of mitochondrial membrane potential (∆Ψm) which
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is coupled to the generation of ATP by the F1/F0 subunits of ATP synthase 78. A
dissipated mitochondrial membrane potential causes activation of the mitochondrial
permeability transition pore (MPTP) with the subsequent release of cytochrome c and the
initiation of apoptosis. For this reason, measurement of ∆Ψm is an important parameter of
mitochondrial function (in terms of ATP production) and has been used as an indicator of
cell death. Exposure of adult rat cardiomyocytes to ethanol caused significant dissipation
∆Ψm as illustrated by JC-1 immunofluorescence (Figure 11).

Sildenafil significantly

preserved the mitochondrial membrane potential (P < 0.001 vs. ethanol alone).
Interestingly, knockdown of PKG with siRNA blocked sildenafil-mediated preservation of
∆Ψm (Figure 12), while overexpression of PKG1α preserved ∆Ψm (Figure 13). These
results provide first direct evidence on the role of PKG in preservation of ∆Ψm following
ethanol treatment in cardiomyocytes. The signaling mechanism by which PKG leads to
preservation of ∆Ψm following ethanol treatment is not clear. Previous investigation form
the laboratory identified a novel PKG-dependent cytoprotective mechanism of sildenafil
against ischemia/reperfusion injury involving phosphorylation of ERK, and GSK3β, and
induction of Bcl-2 34. GSK3β is the phosphorylation target of phosphatidylinositol 3kinase/Akt 79. Activation of GSK3β has been shown to induce myocardial apoptosis 80 by
Akt 81. Hypoxic preconditioning, which also activates PKC, was shown to phosphorylate
and inhibit GSK3β and cause protection in adult cardiomyocytes, through its ability to
modulate mitochondrial permeability transition, a key component of mitochondriamediated cardiac cell death following ischemia-reperfusion 82. Moreover, PKGIα
overexpression in cardiomyocytes enhanced phosphorylation of Akt, ERK1/2, and JNK,
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increased Bcl-2, inducible nitric-oxide synthase, endothelial nitric-oxide synthase, and
decreased Bax expression. Interestingly, 5-HD and glibenclamide (the KATP channel
blockers) abolished PKGIα-mediated protection against necrosis and apoptosis 83.
Another interesting observation in the present study is the role of mitochondrial
KATP channels in protection against ethanol toxicity in cardiomyocytes and the intact heart.
When co-treated with ethanol, sildenafil and 5-HD, an increased rate of necrosis was
observed as compared to ethanol and sildenafil. 5-HD blocked sildenafil-mediated
preservation of ∆Ψm in the presence of ethanol as well (Figure 15). Moreover, sildenafil
induced preservation of cardiac function following treatment of mice with ethanol was
blunted by 5-HD (Figure 17).

During an energy crisis, such as ischemia, mitoKATP

channels may open and in doing so, an inward rectifying current is created. This current
allows for the maintenance of the mitochondrial membrane potential and buffers the
mitochondria against accumulating calcium and prevents cellular swelling.
Pharmacological agents that open mitoKATP provide a strong preconditioning-like signal to
cardiac myocytes and enable them to survive ischemic insult. Garlid et al. first proposed
that mitoKATP channels were involved in the cardioprotective effect 84. By using
reconstituted mitochondrial vesicles or isolated mitochondria and measuring potassium
flux, these investigators demonstrated that heart and liver mitoKATP channels shared
pharmacological properties with the channels found in sarcolemma while possessing a
distinct profile. Furthermore, it was shown that opening of mitoKATP channels leads to the
generation of reactive oxygen species (ROS) by the mitochondria and represents an
important mechanism that is required for the cardioprotective effect of IPC 85,86. Opening
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of these channels allowed potassium to enter the mitochondrial inner matrix, which causes
generation and release of ROS from the respiratory chain 87. ROS then act as second
messengers to activate a downstream pathway of protective kinases, including protein
kinase C (PKC), that finally converge on the cardioprotective end effector. Studies from
our laboratory have shown that sildenafil induces a preconditioning-like stimulus and
promote cardiomyocytes survival via opening of mitoKATP channels 33. Whether such a
pathway of ROS acting as second messengers to activate a downstream pathway of
protective kinases, such as PKC is operative in sildenafil-induced protection against
alcohol toxicity needs investigations in the future.
In the present study, ethanol treatment caused significant increase in ROS
production, which is clearly indicated by enhanced intensity of DCF fluorescence (Figure
16, P < 0.001 vs. control). Co-treatment with sildenafil and ethanol attenuated ethanolinduced ROS production while sildenafil alone had no effect on ROS production as
compared with control. Excessive ethanol intake is known to trigger oxidative stress and
apoptosis via activation of stress signaling 84,88. Zhang et al reported elevated superoxide
(O2- ) production and protein carbonyl formation in murine hearts following chronic
ethanol intake 75. Enhanced O2- and oxidative stress are well known to promote cardiac
contractile and intracellular Ca2 + abnormalities as well as interstitial fibrosis 89. It has been
demonstrated that ethanol may promote free radical generation through direct and indirect
mechanisms such as aldehyde oxidase and xanthine oxidase-mediated oxidation, leading to
accumulation of O2- and oxidative stress 90. The mechanism by which sildenafil
attenuates ROS generation following alcohol treatment is unclear. However, recent studies
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from our laboratory have shown that chronic treatment with the long-acting PDE-5
inhibitor, tadalafil protected against myocardial ischemia/reperfusion injury in a type 2
diabetic mouse via suppression of oxidative stress 91. In these studies, tadalafil treatment
attenuated NADPH oxidase activity and expression of NADPH oxidase subunits pRac-1
and gp91phox and reduced lipid peroxidation in type 2 diabetic hearts. Furthermore,
tadalafil treatment preserved the ∆Ψm after ischemia/reoxygenation injury in
cardiomyocytes isolated from diabetic mice, which is consistent with the effect of
sildenafil in preservation of ∆Ψm following treatment with ethanol (Figure 11). In the
present study, we did not measure NADPH oxidase activity or the expression of the
enzyme subunits following treatment with ethanol in cardiomyocytes. There has been very
limited work done on elucidating the source of oxidative stress in the heart following
chronic treatment with alcohol. A recent preliminary report suggested that that chronic
alcohol intake led to upregulated p47phox (but not p67phox) in the heart, which could be
one of the potential sources of ROS generation. Future studies are required to thoroughly
address the source of radical generation following alcohol toxicity in the heart.

Conclusions and Future Directions

Our results convincingly show that sildenafil provided significant protective effect
against alcohol-induced toxicity in adult cardiomyocytes and preserved cardiac function
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following treatment of mice with alcohol. There could be potential clinical utility of this
work for treatment of alcohol-induced cardiomyopathy. We recognize that abstinence
from alcohol represents the ultimate treatment to prevent alcohol-induced cardiomyopathy.
However, in cases where the immediate cessation of alcohol consumption is not possible,
sildenafil may provide protection against further loss of cardiomyocytes as a result of
apoptosis with continuing alcohol consumption. Thus, sildenafil treatment could preserve
cardiac function until such a time that stopping the cycle of alcohol abuse is possible.
Given the excellent safety profile of sildenafil in treating erectile dysfunction, we believe
that the use of sildenafil for the treatment/prevention of alcohol cardiomyopathy could be
promising. Today, close to 100 clinical trials with PDE-5 inhibitors have been completed
or ongoing which focus on the potential cardiovascular benefits (Clinical Trials.gov).
Clinically, Revatio (sildenafil) is used for treatment of pulmonary arterial hypertension to
improve exercise ability and slow down worsening changes in the physical condition of
patients. Revatio comes in a 20-mg pill that is taken 3 times a day. Moreover, studies of
sildenafil on heart failure patients have reported improved exercise capacity, coupled with
reduced pulmonary vascular resistance and better endothelial function 92. Three clinical
trials have been initiated to test the utility of PDE5 inhibitors for patients with muscular
dystrophy. The REVERSEDBMD focuses on the heart and test sildenafil for the treatment
of Duchenne and Becker dystrophy (Clinicaltrials.gov: NCT01168908). Several other
studies also indicated that PDE-5 inhibition with sildenafil has a therapeutic promise for
stroke, neurodegenerative diseases and potentially other circulatory disorders29. Our work
was mainly focused on demonstrating the protective effect of sildenafil against acute
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alcohol cardiotoxicity at the cellular level and in the intact heart. Future investigations are
needed to demonstrate similar efficacy of sildenafil in a chronic model of alcohol
cardiomyopathy in order to build more compelling case for initiation of clinical trials in
humans.

69

Figure 20. Proposed Mechanism. PDE-5 Inhibitors enhance the accumulation of cGMP
and subsequent PKG activity. In the present study we utilized several strategies, to
elucidate the role of sildenafil in protection against ethanol, including pharmacologic
inhibition on PDE-5 with sildenafil, knockdown of PKG with siRNA, overexpression of
PKG, inhibition of mitoKatp with and 5-HD. The mechanism by which PKG activation
leads to mitoKatp opening and inhibition of MPTP is not currently known.
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